Document 0868
 DOCN  M9480868
 TI    Radiometric susceptibility testing of Mycobacterium tuberculosis against
       second-line drugs.
 DT    9410
 AU    Salfinger M; Gross W; Kornblum J; Laszlo A; Pfyffer G; Roberts G;
       Siddiqi S; NY State Dept. of Health, Albany.
 SO    Abstr Gen Meet Am Soc Microbiol. 1994;94:197 (abstract no. U-138).
       Unique Identifier : AIDSLINE ASM94/94313077
 AB    AIDS epidemic, deterioration of the public health infrastructure and
       inadequate training of health care providers are some factors
       contributing to the increase of tuberculosis (TB), especially
       multidrug-resistant TB. In vitro drug susceptibility testing is now
       required for all TB patients. Since faster turnaround times in the TB
       laboratory are necessary, we compared the radiometric technique with the
       conventional Middlebrook 7H10 agar method for susceptibility to
       second-line drugs in a 3 phase study. In phase I, 10 susceptible M.
       tuberculosis strains were tested in the BACTEC system against the
       following drugs and concentration (mcg/ml): amakicin (AN, 1.0, 2.0,
       4.0), capreomycin (CM, 1.25, 2.5, 5.0), ciprofloxacin (CIP, 0.5, 1.0,
       2.0), clofazimine (CLO, 0.25, 0.5, 1.0), cycloserine (CS, 50, 60, 70),
       ethionamide (ETA, 1.25, 2.5, 5.0), kanamycin (KM, 1.25, 2.5, 5.0),
       ofloxacin (OFL, 0.5, 1.0, 2.0, 4.0). In phase II, specially selected 20
       isolates with some strains resistant to each drug were tested. Drug
       concentrations were adjusted based on the results in Phase I. CIP was
       dropped and rifabutin (RBT, 0.5, 1.0, 2.0) was included. The following
       preliminary critical concentrations (mcg/ml) for radiometric method were
       established: AN 1.0, CM 2.5, CLO 0.25, CS 100.0, ETA 1.25, KM 2.5, OFL
       2.0, and RBT 1.0. Final recommendations will be made after finishing
       testing 30-50 recent clinical isolates in phase III.
 DE    Antibiotics/*TOXICITY  AIDS-Related Opportunistic Infections/DRUG
       THERAPY  Capreomycin  Comparative Study  Drug Resistance, Microbial
       Human  Microbial Sensitivity Tests/*METHODS  Mycobacterium
       tuberculosis/*DRUG EFFECTS/GROWTH & DEVELOPMENT/  ISOLATION & PURIF
       Species Specificity  Tuberculosis, Pulmonary/COMPLICATIONS/DRUG THERAPY
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).